# Progress Note 07 — Focused Visit (Care-plan review)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Samuel Johnson (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-EN008-SYN
- Date: 2026-09-28
- Fictional facility: St. Posthumous Health Center
- Fictional author: Catriona Bell, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Care-plan review)

## Chief complaint

Six-month review of depression and tics. **S**

## History of present illness

Mr. Johnson returns six months after his first visit and four weeks after his back strain, which settled within a week. His mood is good: he has finished a large part of his book and is back among his friends every day. Night sweats are less. He finished the eight sessions of behavioral therapy for tics in the summer and still uses the competing responses when he wants to; he says the remaining tics bother other people more than they bother him. His fecal immunochemical test and HIV test from the preventive visit were negative. **S**

| Element | Detail |
|---|---|
| Sertraline | 100 mg daily |
| Mood | PHQ-9 4; GAD-7 5 |
| Tics | Behavioral therapy completed |
| Back | Resolved |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | Night sweats much less; no weight change |
| Musculoskeletal | Negative | No back pain |
| Neurological | Positive | Tics present but less frequent |
| Psychiatric | Negative | Mood good; no thoughts of suicide or self-harm |

4 systems reviewed. **S**

## Current medications

- Sertraline 100 mg oral tablet, one tablet by mouth once daily **S**

## Allergies

- No known allergy **S**

## Objective

BP 122/76 mmHg; pulse 74 bpm; respirations 14/min; temperature 36.6 °C; oxygen saturation 98% on room air; weight 98.8 kg; BMI 29.5 kg/m². All vital signs are synthetic.

PHQ-9: 4; GAD-7: 5. All results are synthetic.

## Change since baseline

- PHQ-9: 21 at baseline, 4 at this visit **S**
- GAD-7: 12 at baseline, 5 at this visit **S**

## Immunizations given today

- Recombinant zoster vaccine, dose 2 of 2 **S**
- Hepatitis B vaccine (HepB-CpG), dose 2 of 2 **S**
- Influenza vaccine, 2026-2027 season **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well; blood pressure 122/76, pulse 74 |
| Neurological | Occasional head-turning tics and soft sounds |
| Psychiatric | Euthymic, expansive in conversation, logical |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Major depressive disorder, recurrent, in remission** (F33.2). Remission: PHQ-9 4. With recurrent episodes since his twenties, the risk of another is high. Safety reviewed: no thoughts of suicide or self-harm. **S**
   - Continue sertraline 100 mg daily for at least a year, and discuss longer maintenance.
   - Psychotherapy monthly.
   - PHQ-9 every three months.
2. **Tourette syndrome** (F95.2). Yale Global Tic Severity Scale: total tic score 22, from 30; impairment 10, from 20. He finds the tics manageable. **S**
   - No medication; booster behavioral sessions if tics worsen.
   - Tic severity scale yearly.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Survey | Depression measure (PHQ-9) | At baseline and at least monthly during acute treatment; every 2 to 4 weeks in continuation | Completed today | 4: remission |
| Medication safety | Sertraline adherence and adverse effects | Every visit in the acute phase; reassess at 2 weeks after starting and after each dose change | Completed today | Adherent; night sweats lessening |
| Medication safety | Interaction review (serotonergic drugs; NSAIDs and anticoagulants with an SSRI) | At the start and with any new medicine | Completed today | The ibuprofen and omeprazole course after the back strain is finished; no other medicines |
| Survey | Suicide-risk review (PHQ-9 item 9 and structured questions since the last visit), safety plan, and the 988 Suicide & Crisis Lifeline | Every visit | Completed today | No thoughts of suicide or self-harm |
| Referral | Psychotherapy (cognitive behavioral therapy with behavioral activation) | Offer to all with moderate or severe depression | Completed today | Monthly |
| Survey | Anxiety measure (GAD-7) | At baseline and with PHQ-9 reviews | Completed today | 5, from 12 |
| Survey | Tic severity (Yale Global Tic Severity Scale, recorded in the note; no LOINC code is used) | At diagnosis and periodically to judge the need for and response to treatment | Completed today | Total tic score 22; impairment 10 |
| Referral | Comprehensive Behavioral Intervention for Tics | Offer as an initial treatment option | Completed today | Eight sessions completed in the summer |
| Medication safety | Tic-suppressing medication (alpha-2 agonist, aripiprazole, or other) | When tics cause impairment that behavioral therapy does not relieve | Not indicated | Tics manageable without medicine |
| Self-management | Zoster, hepatitis B, and influenza vaccines | Per the adult schedule | Completed today | Zoster dose 2, hepatitis B dose 2, and influenza vaccine given today |

## Goal progress

- PHQ-9 response (at least a 50% fall) by three months and remission (below 5) by six months. Outcome by 2026-09-28: PHQ-9 10 at eleven weeks (from 21) and 4 at six months. **S**
- Back at daily writing and seeing friends again by three months. Outcome by 2026-06-22: Writing most mornings and dining with friends several times a week. **S**
- Fewer and less disruptive tics, judged by him and by the tic severity scale, by six months. Outcome by 2026-09-28: Yale Global Tic Severity Scale total tic score 22 from 30 and impairment 10 from 20; he finds the remaining tics manageable. **S**
- Safety plan in place and reviewed at every visit. Outcome by 2026-09-28: Reviewed at every visit; no suicidal thoughts at any visit. **S**

## Guideline basis

- Practice guideline recommendations summary: Treatment of tics in people with Tourette syndrome and chronic tic disorders (Pringsheim T, et al. Neurology 2019;92(19):896-906) (2019), American Academy of Neurology
- VA/DoD Clinical Practice Guideline for the Management of Major Depressive Disorder (2022), United States Department of Veterans Affairs and Department of Defense
- VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024), United States Department of Veterans Affairs and Department of Defense
- CMID: Clinical Monitoring Intelligence Database, depression, bipolar, and mood disorders monograph (2026), Aether Forge
- Adult Immunization Schedule by Medical Condition and Other Indication (2026), Centers for Disease Control and Prevention

## Follow-up

- Review in three months with PHQ-9. Neurology as needed. **S**

